Viia E. Archer-Valge

Early Oncology R&D
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

PARP inhibition generates enhanced CD8+ central memory T cells by transcriptional and metabolic reprogramming.

PARP inhibition generates enhanced CD8+ central memory T cells by transcriptional and metabolic reprogramming.

Journal: Nature immunology

Published: June 16, 2025

KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer.

KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer.

Journal: Cancer cell

Published: August 08, 2024

Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Breast Cancer.

Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination-Deficient Breast Cancer.

Journal: Cancer research

Published: July 23, 2024

Discovery and characterisation of quinazolines and 8-Azaquinazolines as NLRP3 agonists with oral bioavailability in mice.

Discovery and characterisation of quinazolines and 8-Azaquinazolines as NLRP3 agonists with oral bioavailability in mice.

Journal: Bioorganic & medicinal chemistry letters

Published: August 22, 2023

Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments.

Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and impact response to immuno-oncology treatments.

Journal: Frontiers in immunology

Published: July 13, 2023

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.

Journal: Nature communications

Published: July 10, 2023

Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation.

Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation.

Journal: Oncoimmunology

Published: September 19, 2022

Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma.

Small Gene Networks Delineate Immune Cell States and Characterize Immunotherapy Response in Melanoma.

Journal: Cancer immunology research

Published: July 14, 2022

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors.

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors.

Journal: Oncoimmunology

Published: June 27, 2022

ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance.

ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance.

Journal: Cancer research

Published: February 07, 2022

Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function.

Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function.

Journal: Frontiers in immunology

Published: November 05, 2020

Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control.

Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 18, 2020

Showing 1-12 of 24

Last Updated: 09/26/2026